Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Substitution of a hydrogen atom with its heavy isotope deuterium entails the addition of one
neutron to a molecule. Despite being a subtle change, this structural modification, known as …

Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …

Abstract Emerging SARS-CoV-2 variants, particularly the Omicron variant and its
sublineages, continually threaten the global public health. Small molecule antivirals are an …

Omicron variant of SARS-CoV-2 has become the predominant variant worldwide. VV116 is
an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies. We conducted an …

Abstract VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-
2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and …